MK-8776, a novel Chk1 inhibitor, exhibits an improved radiosensitizing effect compared to UCN-01 (cas 112953-11-4) by exacerbating radiation-induced aberrant mitosis
-
Add time:07/30/2019 Source:sciencedirect.com
Checkpoint kinase 1 (Chk1) is an evolutionarily conserved serine/threonine kinase that plays an important role in G2/M checkpoint signaling. Here, we evaluate the radiosensitizing effects of a novel selective Chk1 inhibitor MK-8776, comparing its efficacy with a first-generation Chk1 inhibitor UCN-01 (cas 112953-11-4), and attempt to elucidate the mechanism of radiosensitization. In a clonogenic survival assay, MK-8776 demonstrated a more pronounced radiosensitizing effect than UCN-01, with lower cytotoxicity. Importantly, radiosensitization by MK-8776 can be achieved at doses as low as 2.5 Gy, which is a clinically applicable irradiation dose. MK-8776, but not UCN-01, exacerbated mitotic catastrophe (MC) and centrosome abnormalities, without affecting repair kinetics of DNA double strand breaks. Furthermore, live-cell imaging revealed that MK-8776 significantly abrogated the radiation-induced G2/M checkpoint, prolonged the mitotic phase, and enhanced aberrant mitosis. This suggests that Chk1 inhibition by MK-8776 activates a spindle assembly checkpoint and increases mitotic defects in irradiated EMT6 cells. In conclusion, we have shown that, at minimally toxic concentrations, MK-8776 enhances radiation-induced cell death through the enhancement of aberrant mitosis and MC, without affecting DNA damage repair.
We also recommend Trading Suppliers and Manufacturers of UCN-01 (cas 112953-11-4). Pls Click Website Link as below: cas 112953-11-4 suppliers
Prev:The phosphoinositide-dependent protein kinase 1 inhibitor, UCN-01 (cas 112953-11-4), induces fragmentation: Possible role of metalloproteinases
Next:Development of a simplified, sensitive high-performance liquid chromatographic method using fluorescence detection to determine the concentration of UCN-01 (cas 112953-11-4) in human plasma) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- UCN-01 (cas 112953-11-4), an anti-tumor drug, is a selective inhibitor of the conventional PKC subfamily08/05/2019
- Controlled release of a protein kinase inhibitor UCN-01 (cas 112953-11-4) from liposomes influenced by the particle size08/04/2019
- UCN-01 (cas 112953-11-4) in combination with topotecan in patients with advanced recurrent ovarian cancer: A study of the Princess Margaret Hospital Phase II consortium08/03/2019
- Development of a highly sensitive high-performance liquid chromatographic method for measuring an anticancer drug, UCN-01 (cas 112953-11-4), in human plasma or urine08/02/2019
- AG490 influences UCN-01 (cas 112953-11-4)-induced cytotoxicity in Glioma cells in a p53-dependent fashion, correlating with effects on BAX cleavage and BAD phosphorylation08/01/2019
- Development of a simplified, sensitive high-performance liquid chromatographic method using fluorescence detection to determine the concentration of UCN-01 (cas 112953-11-4) in human plasma07/31/2019
- The phosphoinositide-dependent protein kinase 1 inhibitor, UCN-01 (cas 112953-11-4), induces fragmentation: Possible role of metalloproteinases07/29/2019
- Celecoxib Enhances the Radiosensitizing Effect of 7-Hydroxystaurosporine (UCN-01 (cas 112953-11-4)) in Human Lung Cancer Cell Lines07/28/2019
- The combination of UCN-01 (cas 112953-11-4) and ATRA triggers differentiation in ATRA resistant acute promyelocytic leukemia cell lines via RAF-1 independent activation of MEK/ERK07/27/2019